

HVC KYOTO 2019

Healthcare Venture Conference KYOTO 2019

Date

July 1st, 2019

Venue

Kyoto Research Park West Bldg #4 B1F

*Please see the web for venue access

Capacity

250 participants (first-come-first-served basis)

*Prior application required

Admission

Free

Inquiries

HVC KYOTO 2019 Secretariat

Kyoto Research Park Corp.

E-mail: hvckyoto@krp.co.jp

TEL: 075-315-9040

Registration URL



主催：日本貿易振興機構(JETRO)、京都府、京都市、京都リサーチパーク株式会社

共催：京都大学産官学連携本部

後援：近畿経済産業局、京都商工会議所、大阪商工会議所、神戸商工会議所、公益財団法人都市活力研究所、NPO法人「関西健康・医療学術連絡会」、

関西健康・医療創生会議、一般社団法人ライフサイエンス・イノベーション・ネットワーク・ジャパン(LINK-J)、NPO法人日本MITベンチャーフォーラム、合同会社SARR

A chance to participate in Japan's most known partnering event for innovative finds in regards to Healthcare.

20+ scientists and venture capitals who wish to expand inside and outside of Japan will be having their English pitch in front of a podium. For those searching for innovative technology in healthcare, please feel free to join the conference.

※HVCKYOTO2019 will be held as a part of JETRO's 「Regional Promotion Project」 and 「Regional Business Conference」
There will be a Japanese-English interpreter. (Will be lending out receivers to those in need) *limited amounts

Program

- 9:30 : Opening remarks
- 9:40 : **Special lecture** Design-driven approaches to drug discovery and translational research
 Rieko Yajima, Ph.D.
Stanford University
Director, Drug Discovery Innovation
SPARK Program in Translational Research
School of Medicine
- 10:15 : Pitch session①
- 12:15 : Lunch break
- 13:15 : Boston session
Startups & ventures from Boston area who wish to develop
their business in Japan will be having their pitch in this session.
- 14:45 : Coffee break
- 15:00 : Pitch session②
- 17:00 : Networking (At the exhibition hall)

※Each session speaker please refer to WEB



HVC KYOTO 2019 Partners

Platinum



Gold



バイエル



田辺三菱製薬




京都大学イノベーションキャピタル株式会社
KYOTO UNIVERSITY INNOVATION CAPITAL CO., LTD.




小林製薬

Silver












		Affiliation	Name of Speaker	Title
1		SkySea Pharmaceutical Inc.	Yuji Kogami	Drug Discovery of Oxytocin related Autism Spectrum Disorder
		2006 AsahiKasei Pharmaceutical 2006-2010 PRISM BioLab Corporation Director 2010- D.D.P. Corporation, CEO & President 2015- SkySea Pharmaceutical Inc., CEO & President		
2		ReguGene Co., Ltd.	Shuji Ikeda	Epigenetic Drug Discovery by Gene Switch
		Ph.D. Managing Director of ReguGene Co., Ltd. and researcher at Chemistry Department, Graduate School of Kyoto University after working as assistant professor and researcher at university, national research institute, and venture company in Singapore.		
3		Cellagility Biomed Pvt. Co.	Kouichi Hasegawa	Enabling Cell Therapy – From India to world –
		Junior Associate Prof. Institute for Integrated Cell-Material Sciences (iCeMS), Kyoto University, and Scientific Advisory board, Cellagility Biomed, India. Previously served as a faculty in University of Southern California, University of Melbourne and iStem, India, and a SAB at Cell Guidance System (UK) and Stem Cell Innovation (Japan).		
4		iBody Inc.	Teruyo Kato	Robust screening of monoclonal antibodies from rabbits and humans
		Graduate school of Nagoya University/R&D section at food material company/Researcher of Project at Knowledge Hub Aichi/JSPS PD Research fellowship/CEO at iBody		
5		ERISA Co., LTD.	Yoshiyuki NOTSU	Companion Diagnostic “AI Program” that enables successful development of therapeutic drugs for Alzheimer’s diseases
		After completion of master’s degree of Graduate School of Agricultural and Life Sciences, the University of Tokyo, engaged in general management for overseas subsidiaries and domestic business development for Japanese research reagents manufacture. After 13 years’ employment, joined two life science start-ups as management. Since October 2017, current position.		
6		Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology	Tadashi Kimura	Disulfide-Rich Peptides, promising scaffolds for pharmaceuticals, agrichemicals and cosmetics.
		Dr. Kimura received Ph.D. from Tsukuba University. He has deep experiences on ion-channel and tarantula venom peptides research. He is a visiting associate professor at united graduate school of drug discovery and medical information science, Gifu University.		
7		School of Dentistry, Health Sciences University of Hokkaido	Takashi Saito	Dentin regeneration therapy using Laminin-derived peptide, Laminin-411 and 511
		The speaker engaged in the research on tooth remineralization and regeneration in UNC Dental Research Center in the United States and AIST in Japan, and then since 2003, has been performing the research on the development of novel therapy for deep dental caries in Health Sciences University of Hokkaido.		
8		Tongue Lab	Jean Michel Maclaure	Paradigm changing curative treatment for sleep apnea.
		<div> <div> 1991 French Certified Public Accountant, Paris –France 1983-1984 Deloitte & Touche -International audit firm, 1989-1995 Lafarge Group- CFO in a subsidiary, 1996-2000 Lindsey Technologies-Paris,France,Denver,USA:Information Technology start up, CFO 1998-2008 CPA PC– Paris France: Merger and Acquisitions </div> <div> 2002-2011 BioQuanta Corp – Aurora, Co, USA - Paris France :Biotechnology start up: co-founder, CEO. 2012-2016 Management consultant: Growth and technology start-up companies (France, Mexico) 2012 Tongue Lab – London UK - Paris France: founder, Chairman & CEO. 2017 Tongue Lab Japan Office </div> </div>		
9		Elcyo Co., Ltd.	Giichi Shibuya	New solution for eye correction “full-range tunable eyeglasses”
		After graduation from Keio University, Shibuya started working at TDK corp. for 30 years since 1984. At Osaka University He has been focusing on the research of Fresnel liquid crystal lens since 2014, and launched Elcyo Co., Ltd. in 2019.		

Boston Session Special Lecture

	Affiliation	Name of Speaker	Title
	Biogen Japan Inc Born in June, 1960 March, 1984 Graduated from Gifu College of Pharmacy March, 2002 Ph.D degree from Molecular Biology from Tokyo University, Graduate School April, 1984~ Janssen Pharmaceutical K.K. April, 2007~ Celgene Corporation April, 2010~ Olympus Corporation January, 2011~ Olympus Biotech Corporation (Boston, USA) June, 2014~ Head of R&D, Biogen Japan Inc. April, 2017~ President & Representative Director, Biogen Japan Inc. November, 2018~ President & Representative Director, Biogen Japan Inc. (Daihyo Torishimariyaku Kaicho)	Shinichi Torii	Introduction for new drug development based on Neuroscience research Shinichi joined Biogen Japan in June 2014 to establish and lead its R&D function in Japan as part of Biogen's 'Tri-Hub' research and development model. He brings his depth knowledge and experience in both academia and the industry to leverage the world-class scientific innovation of Biogen. Prior to Biogen, he spent many years as a researcher in academia and expanded his career path into the pharmaceutical and medical device industries including Janssen Pharmaceutical and Olympus Biotech. In his past experiences, Neurology research and development including MS, Alzheimer's diseases and growth factors, NGF and BDNFs are one of his scientific interests as not only "bench to bed" but also "bed to bench" collaborations with Japanese basic and clinical researchers.

Boston Session Pitch Presenters

	Affiliation	Name of Speaker	Title
1	 biolabs 1998-2002 Colorado State University BioChemistry, Microbiology 2007-2010 Ludwig-Maximilians University Munich, Doctor of Philosophy, (Ph.D), Pharmaceutical Biology and Natural Sciences	Christine Kressirer, PhD,	BioLabs, the experience of a biotechnology company in a shared-laboratory facility 2011-2018 The Forsyth Institute Final title - Director of Core and Laboratory services 2018- Site Director, Tufts Launchpad Biolabs
2	 UCHU Biosensors, Inc. Co-Founder, CEO of UCHU Biosensors, Inc. 2014 - Researcher, Dana Farber Cancer Institute Studied anti-apoptotic cell signaling pathways for drug development 2015 - Researcher, Tufts Sackler School of Biomedical Sciences Grew artificial skin from IPS cells to study chronic wound healing	Daniel Weinstein	Intraoral Health Monitor 2016 - Summer Researcher, Technion Institute of Technology Characterized and validated response of nanoscale optical biosensors 2018 - Graduated cum laude with a BSBME (bachelors of science in biomedical Engineering) from Tufts University School of Engineering
3	 Mytide Therapeutics 2013 B.S. Maine Maritime Academy, Valedictorian 2013 American Bureau of Shipping Fellowship 2014 MEngM, Massachusetts Institute of Technology 2019 PhD, Massachusetts Institute of Technology 2019 Cofounder, Mytide Therapeutics	Dale A. Thomas III	High-throughput Peptide Manufacturing for Therapeutic Research and Drug Discovery
4	 DropGenie 2011 MSc, Medical Genetics, University of British Columbia, Vancouver, Canada	Alison Hirukawa	Automating gene editing using a digital microfluidics platform 2017- PhD, Biochemistry, McGill University, Montreal, Canada 2018- Co-founder, Chief Product Officer, DropGenie, Boston MA
5	 North Shore InnoVentures Chris is the President and CEO of NSIV. As a leader in the Boston innovation ecosystem Chris and the team at North Shore InnoVentures (NSIV) are actively involved in supporting innovation-driven companies to realize and deliver impact. Not only does NSIV support companies through start of the art lab facilities; but, also, importantly, with business and leadership support through programs, services, community partnerships and mentoring.	Christopher R.C. Ilsley	Innovate faster, Climb higher NSIV is an accredited 'soft landing' facility for the International Business Incubator Association (InBIA). This accreditation validates that NSIV has a robust and supportive services and program to help international companies to enter the Boston and North American life science community. Chris moved to Boston as Head of Science and Innovation at the British Consulate Boston, from Cambridge, UK, where he worked as an advisor to UK companies looking identify and develop international partnership opportunities.
6	 Genomic Expression Scientist/CEO with a mission to cure cancer. Started Genomic Expression together with her brother, after her parents were diagnosed with cancer. The company raised \$8M to conduct 4 clinical trials focusing on women cancer first. OneRNA™ finds the best drug for the patient and the best patient for the drug by sequencing RNA. Genomic Expression was in the top 10 of the XTC, also won the Lyfebulb and the EUTop50 award, and presented at the European Parliament and UN in New York.	Gitte Pedersen	Title: OneRNA™: a paradigm shift to truly individualized treatment Prior to Genomic Expression, Gitte advised a number of SMEs of biotech as well as the Danish Ministry of Foreign Affairs with deal resume +\$1B. Gitte Pedersen has a master in Chemical Engineering and a bachelor in International Trade. She recently joined Pipeline Angels and made her first angel investment.
7	 Cellanx Diagnostics 1988-1992 Solo-Practice, Internal Medicine 1995-1999 The Boston Consulting Group, USA 1999-2000 Sanford Bernstein, Equities Analyst, NY, NY 2000-2001 Ivy Consulting Enterprises, Health Care Consulting, Boston, MA 2001-2002 Collagenesis, a tissue engineering firm, Boston, MA 2002-2007 Fletcher Spaght, Inc., Health Care Consulting, Director	Guy L. Fish	Stratifying indolent from aggressive cancers: it's the biology, not the histology 2004-2010 Massachusetts Board of Registration in Medicine, MD Licensing Board, Chairman of Licensing 2010-2016 Dubai Health Care City Licensing Board, Chairman of Board 2005-2018 Fletcher Spaght Venture, Health Care Venture Capital, Vice President 2007-2019 Fletcher Spaght, Inc., Health Care Consulting, Senior Vice President 2019 Cellanx Diagnostics, CEO
8	 Thrive Bioscience, Inc. Mr. Farb-Horch is CEO and President of Thrive Bioscience (Boston, Massachusetts) which provides instruments and software tools for the automation of cell culture and stem cell culture, a neglected yet critical area for biomedical research. Thrive has raised \$20M to-date, has filed 46 patent applications and is in beta testing of its first of a family of instruments with Harvard Stem Cell Institute, Massachusetts General Hospital and Stanford University Stem Cell Core and others. Mr. Farb-Horch has actively participated in the founding of over 10 life sciences, artificial intelligence and software companies and has had four exits with one billion dollars or more. He has founded and served on the Boards of numerous companies, including Exact Sciences	Thomas Forest Farb-Horch	Analytics, AI & Automation in Cell Culture & Stem Cell Culture (NASD: EXAS), Fair Isaac (NYSE: FIC), Redwood Trust (NYSE: RWT), HNC Software (acquired by Fair Isaac), Retek Systems (acquired by Oracle) and Saf-T-Med (acquired by Becton Dickinson). Mr. Farb-Horch has served as President, COO and/or in the senior management of numerous companies, including Thrive Bioscience, Inc., Indevus Pharmaceuticals and Cytlyc. Mr. Farb has also been a Trustee for numerous non-profit organizations including North Shore InnoVentures (an incubator/accelerator in the Boston area), Dana Farber Cancer Institute and Asia America Chamber of Commerce. Mr. Farb is a graduate of Harvard University.
9	 Biobot Analytics, Inc 2011 B.Eng. in Civil Engineering, University of Tokyo, Japan 2014 M.Sci. in Environmental Engineering, Massachusetts Institute of Technology, USA 2017 PhD in Environmental Engineering, Massachusetts Institute of Technology, USA 2017 Spatial Epidemiologist and Product Manager, Biobot Analytics, USA	Noriko Endo	Leveraging wastewater as a window into population health. Dr. Endo is as engineer who works at the intersection of environmental engineering and public health. She has extensive field experiences in Africa, Asia, and North America on health-related projects, such as malaria transmission, human metabolomics, and antimicrobial resistance.
10	 Canairy 2015 BS, Biology, Hunter College 2016-2019 PhD Candidate, Computational Biolgy, Icahn School of Medicine at Mount Sinai 2018 Co-founder: A.I. chemistry, A.I. based drug discovery platform 2019 CEO and Co-Founder of Canairy: Biotechnology Start up	Rayees Rahman	App based mangement of respiratory disease using cough sounds and machine learning
11	 PORTAL INSTRUMENTS, INC. 2008 BS Mechanical Engineering 2008-2011 Cambridge Consultants, Medical Device Engineer 2011-2014 Fractyl Inc., Surgical Device for Diabeaties, Engineer 2014- present Portal Instruments, VP Engineering	Andrew Coats	Innovation in Drug Delivery: Needle-Free Auto-Injector

		Affiliation	Name of Speaker	Title
1		ARTham Therapeutics Inc.	Hiroshi Nagabukuro PhD	Delivering medicines that matter and maximizing pharma asset value through robust and efficient industry-academia collaborations
		Dr. Hiroshi Nagabukuro is a co-founder, COO/CSO of newly launched ARTham Therapeutics Inc. He has strong background in pharmacology with >20 years' experience of drug discovery research in both Japan and US. Dr. Nagabukuro also holds special appointed professorship at Oita University Medical School.		
2		Luxonus Inc.	Sadakazu Aiso M.D., PhD.	Photoacoustic 3D imaging opens a Door to Vascular Health Science
		Our new diagnostic equipment using Photoacoustic Imaging technology is non-bombarded, non-invasive, and enables ultra-high resolution 3D imaging of vessels such as blood vessels and lymph vessels. Furthermore, the oxygen saturation of the bloodstream can be visualized, and it is expected to be utilized for preoperative planning and drug effect verification.		
3		aceRNA Technologies	Shin-Il Kim	Solution provider for new pharmaceutical modalities
		I obtained Ph.D in 2008 from University of Wisconsin – Madison. After a postdoc at University of California - SF, I received JSPS Postdoctoral Fellowship to study iPSCs at CIRA, Kyoto University under supervision of Drs. Yamanaka and Woltjen. Currently, I am a director of R&D division at aceRNA Technologies.		
4		HAPPY PROJECT LLC	Masa Kawamukai	Respect aging society and end-of-life medical care at home by utilizing IoT/AI
		He was born and grew up in Kyoto and studied at Liberal Arts College in Oakland, CA both undergraduate and graduate school. He worked one of big accounting firm and fingerprint venture company in Silicon Valley until dot-com bubble. Since back in Japan, he worked in several industries including investment firm, hospitality, IT. Now he runs his own small consulting firm and an associate professor /producer at Liberal Arts Innovation Center in Kyoto University Art & Design.		
5		Melody International Ltd.	Yhuko Ogata	Save all Mothers and Babies Lives around the Globe ~Perinatal e-Health platform
		Master of Engineering, Kyoto University Graduate School of Engineering, Nuclear Engineering. I succeeded in commercialization of the first EMR for Perinatal period at previous company which I founded in 2002. In 2009, I was awarded "Japan Venture Awards 2009" by the government. Taking advantage of the experiences of medical ICT, I started Melody International in 2015. The corporate mission as "Providing safe and secure deliveries for all mothers around the World.		
6		United Immunity, Co., Ltd.	Naozumi Harada, Ph.D.	Transforming Cold Tumors Hot: A Novel Strategy to Fight Off Immune Checkpoint Inhibition-Resistant Tumors
		20+ years research experience in pharmaceutical companies and biotech. In a recent decade, has studied cancer immunotherapy focusing on tumor immune resistance and exploiting nanotechnology to immunotherapy. Recently invented a technology to improve macrophage function using a Kyoto University-originated unique nanoparticle. To make it as a new weapon against cancer, launched United Immunity.		
7		Metcela Inc.	H. Joon Paek, Ph.D.	Revolutionizing the Way We Treat Heart Failure
		After completing university, he established a network of researchers in the US and abroad based on regenerative medicine and medical devices using adipose-derived stem cells, and has led joint research and business. Master's : Degree Kyoto University Graduate School of Engineering doctorate : Brown University, Department of Biology		
8		Kyoto University	Yuki Yamamoto, M.D., Ph.D.	Innovating drug discovery for respiratory diseases using iPS-cell technology
		I have been working as a researcher of iPS-cell technology for respiratory diseases. I am preparing for a start-up based on our technologies. I have seen many patients with respiratory diseases as a respiratory physician. Now I will give our technologies back to patients as novel drugs.		
9		The Elegant Monkeys Ltd.	Idan Lahav	Kenko Technology - Digitizing Human Emotions.
		Idan is the VP R&D of The Elegant Monkeys, leading the research and development of Kenko Technology, overcoming challenges and advancing the technology to where it needs to be. Idan holds a Master of Business Administration in Management of Technology, Innovation & Entrepreneurship from Tel Aviv University and a Bachelor in Computer Science. Before joining the Elegant Monkeys, Idan served for 6 years as an officer in an elite intelligence unit for the Israeli Defence Forces and later led development teams for 3 years in the Israeli start-up ecosystem.		